EU $2 AstraZeneca Corona 19 Vaccine, US $4… “Price varies according to quantity”

Input 2020.12.19 07:05

–

Even if countries around the world contract for the same company’s Corona 19 vaccine, the purchase price was found to be different. AstraZeneca’s Corona 19 vaccine, which the Korean government plans to supply in Korea as early as next February, is at the level of 2 dollars in the European Union, but 4 dollars in the United States. It is an analysis that the situation of each country and the quantity of purchases had an effect.

According to the Washington Post (WP) on the 18th (local time), the price of a single dose of AstraZeneca Corona 19 vaccine was $2.19 in the EU, 45.3% cheaper than in the United States ($4).

Pfizer’s and German Bioentech’s Corona 19 vaccine was also $14.76 in the EU, 24.3% cheaper than the U.S. ($19.5), and the Sanofi-GlaxoMiscline (GSK) vaccine was also $9.3 in Europe, 11.4 from the U.S. ($10.5). % Was lower.

On the other hand, the cost of a single dose of the Corona 19 vaccine developed by Modena in the United States is $18 in the EU, which is 20% more expensive than the United States ($15). The Janssen (Johnson & Johnson) vaccine in the U.S. was also $10.46 in the EU, 4.6% higher than the U.S. ($10).

WP analyzed the prices of Pfizer’s COVID-19 vaccine in the US and Europe, “some may have reflected that the EU subsidized the development of this vaccine.” The EU and Germany donated $580 million to Bioentech, which jointly developed the Pfizer vaccine.

WP also saw that there may be a price difference depending on the special agreement of the contract, such as a clause limiting the liability of pharmaceutical companies when side effects occur.

The Korean government has signed a contract to purchase a COVID-19 vaccine with AstraZeneca, and only purchase terms and supply confirmations have been signed with Pfizer, Modena, and Janssen. The government plans to close the vaccine supply contract with Pfizer and Moderna in December and with Janssen by January next year.

Im In-taek, head of the Health Industry Policy Bureau of the Ministry of Health and Welfare, said at the Corona 19 briefing on the 18th, “The price policy of global vaccine companies is a discrimination policy and discriminates according to whether they are in high-income countries or poor countries.” According to the discrimination,” he said.

–

– .

Related posts:

Labor disputes are on the rise

Federal Court of Justice Hearing: Can Companies Advertise as "Climate Neutral"?

Scandalous Practices of Landscaping Company "Paysagement Communautaire" Lead to Fines and Complaints

New Ownership and Services at Bourgogne Company: Gérald Esnard Takes the Helm